John M Bennett| - JoVE Visualize

Showing results (41-50 of 131) with videos related to

Pageof 14

Sort By:

Synlett : Accounts and Rapid Communications in Synthetic Organic Chemistry|August 9, 2021

Stereoselective Synthesis of (4S,5S)-5-Vinyloxazolidin-2-one-4-carboxylate as a β-Vinylserine Synthetic Equivalent by Vinyl Grignard Addition to an N-Tosyl Version of Garner's AldehydeErnest G Nolen, Yuqi M Cao, Brynn D Lewis, et al.

Leukemia Research|September 15, 2009

Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemiaSteven L Allen, Jonathan E Kolitz, Ante S Lundberg, et al.

Leukemia Research|May 18, 2007

Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interfaceFriedrich Wimazal, Christa Fonatsch, Renate Thalhammer, et al.

Leukemia Research|September 17, 2011

Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDSPeter Valent, Barbara J Bain, John M Bennett, et al.

American Journal of Hematology|July 30, 2004

Donor cell myelodysplastic syndrome after allogeneic stem cell transplantation responding to donor lymphocyte infusion: case report and literature reviewRami Komrokji, Jainulabdeen J Ifthikharuddin, Raymond E Felgar, et al.

Leukemia & Lymphoma|October 21, 2003

A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486)Peter H Wiernik, Peter A Cassileth, Traci Leong, et al.

Leukemia Research|March 22, 2017

New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS typesCorinna Strupp, Kathrin Nachtkamp, Barbara Hildebrandt, et al.

Leukemia Research|March 24, 2004

A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylateBrenda Wittman, John Horan, Joanna Baxter, et al.

Journal of Visualized Experiments : Jove|January 25, 2018

Preparation of N-(2-alkoxyvinyl)sulfonamides from N-tosyl-1,2,3-triazoles and Subsequent Conversion to Substituted Phthalans and PhenethylaminesJohn M Bennett, Jonathan D Shapiro, Krystina N Choinski, et al.

Leukemia Research|April 12, 2003

Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteriaPeter Valent, Cem Akin, Wolfgang R Sperr, et al.

Pageof 14

Showing results (41-50 of 131) with videos related to

Sort By:

Pageof 14

Synlett : Accounts and Rapid Communications in Synthetic Organic Chemistry|August 9, 2021

Stereoselective Synthesis of (4S,5S)-5-Vinyloxazolidin-2-one-4-carboxylate as a β-Vinylserine Synthetic Equivalent by Vinyl Grignard Addition to an N-Tosyl Version of Garner's AldehydeErnest G Nolen, Yuqi M Cao, Brynn D Lewis, et al.

Leukemia Research|September 15, 2009

Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemiaSteven L Allen, Jonathan E Kolitz, Ante S Lundberg, et al.

Leukemia Research|May 18, 2007

Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interfaceFriedrich Wimazal, Christa Fonatsch, Renate Thalhammer, et al.

Leukemia Research|September 17, 2011

Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDSPeter Valent, Barbara J Bain, John M Bennett, et al.

American Journal of Hematology|July 30, 2004

Donor cell myelodysplastic syndrome after allogeneic stem cell transplantation responding to donor lymphocyte infusion: case report and literature reviewRami Komrokji, Jainulabdeen J Ifthikharuddin, Raymond E Felgar, et al.

Leukemia & Lymphoma|October 21, 2003

A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486)Peter H Wiernik, Peter A Cassileth, Traci Leong, et al.

Leukemia Research|March 22, 2017

New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS typesCorinna Strupp, Kathrin Nachtkamp, Barbara Hildebrandt, et al.

Leukemia Research|March 24, 2004

A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylateBrenda Wittman, John Horan, Joanna Baxter, et al.

Journal of Visualized Experiments : Jove|January 25, 2018

Preparation of N-(2-alkoxyvinyl)sulfonamides from N-tosyl-1,2,3-triazoles and Subsequent Conversion to Substituted Phthalans and PhenethylaminesJohn M Bennett, Jonathan D Shapiro, Krystina N Choinski, et al.

Leukemia Research|April 12, 2003

Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteriaPeter Valent, Cem Akin, Wolfgang R Sperr, et al.

Pageof 14